Yang X, Qiang Q, Li N, Feng P, Wei W, Hlscher C (2022) Neuroprotective mechanisms of glucagon-like peptide-1-based therapies in ischemic stroke: an update based on preclinical research
"I highly recommend implementing diet, exercise and lifestyle changes with or without the medications," Carpenter comments
Semaglutide was the most cost-effective treatment compared to exenatide, dulaglutide, liraglutide, or no treatment in short-term analyses (approximately one and a half years) that assessed quality-adjusted life years and incremental cost-effectiveness ratios [135,136,137,138,139,140,141,142,143,144]
Yet it is Lillys newest drug, tirzepatide, which poses a more serious threat to Novos market dominance